raav2/5-hnaglu
Gene therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2013 (NCT03300453)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-N-acetylglucosaminidaseSupplementation
supplementation - NAGLU
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03300453 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2013 | Hopitaux Universitaires Paris-Sud, Institut Pasteur, UniQure N.V., Venn Life Sciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hopitaux Universitaires Paris-Sud | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Institut Pasteur | Academic/Hospital | 1 | 0 | 1 | 2013 |
| UniQure N.V. | For profit | 1 | 1 | 1 | 2013 |
| Venn Life Sciences | For profit | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1